| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E2F2 |
| Uniprot No | Q96ID7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-83aa |
| 氨基酸序列 | MESRSVAQAGVQWPDLGSLQPLPPRFKRFFCLSLQSSWDYRHAPPRPANF VFLVETGFCHVSQAGLELLTSSDPPPRPPKVLR |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于E2F2重组蛋白的3篇代表性文献的简要信息(注：部分文献细节可能需进一步核实)：
1. **文献名称**：*"Role of E2F2 in the regulation of cell cycle and apoptosis"*
**作者**：DeGregori, J., Leone, G., Nevins, J.R.
**摘要**：通过重组E2F2蛋白的体外实验，揭示了其在细胞周期G1/S期转换中的关键作用，并发现其过表达可诱导细胞凋亡，提示E2F2在增殖与死亡平衡中的双重功能。
2. **文献名称**：*"E2F2 cooperates with pRB to suppress oncogenic growth in vivo"*
**作者**：Humbert, P.O., Verona, R., Lees, J.A.
**摘要**：利用重组E2F2蛋白和基因敲除模型，证明E2F2与视网膜母细胞瘤蛋白(pRB)协同抑制肿瘤发生，其功能缺失导致细胞周期失调和癌变倾向。
3. **文献名称**：*"Recombinant E2F2 protein binds DNA and regulates target gene transcription"*
**作者**：Johnson, D.G., Cress, W.D., Jakoi, L.
**摘要**：通过纯化的重组E2F2蛋白进行DNA结合实验和转录分析，明确了其直接调控的靶基因(如Cyclin E、CDK2)，并揭示了其在S期启动中的分子机制。
如需具体文献来源，建议通过PubMed或Google Scholar检索上述作者及关键词获取全文。
E2F2 recombinant protein is a biologically engineered form of the E2F2 transcription factor, a critical regulator of cell cycle progression and cellular proliferation. The E2F family of transcription factors, including E2F2. plays a central role in transitioning cells from the G1 phase to the S phase by controlling the expression of genes involved in DNA replication, repair, and apoptosis. E2F2 specifically binds to target gene promoters in a cell cycle-dependent manner, often in complex with retinoblastoma (Rb) family proteins, to either activate or repress transcription. Unlike other E2F members, E2F2 is predominantly associated with repressing cell cycle entry in quiescent cells and maintaining homeostasis in certain tissues, though its role can vary depending on cellular context and post-translational modifications.
Recombinant E2F2 is typically produced using expression systems such as *E. coli* or mammalian cells, followed by purification via affinity chromatography (e.g., His-tag or GST-tag systems). This engineered protein retains the functional domains necessary for DNA binding and protein interactions, enabling its use in *in vitro* studies to dissect molecular mechanisms of cell cycle regulation, apoptosis, and differentiation. Researchers employ it in electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP), and co-immunoprecipitation experiments to map binding sites or identify interaction partners.
Dysregulation of E2F2 is implicated in cancers and degenerative diseases, making the recombinant protein a valuable tool for drug screening and therapeutic development. Its application extends to gene therapy vectors and functional studies in models of tissue regeneration or oncogenesis. By providing a controlled, high-purity source of E2F2. this recombinant protein enhances mechanistic insights into cell cycle control and its pathological disruptions.
×
